Document Detail

The cardiovascular effects of vecuronium (ORG NC45) and pancuronium in patients undergoing coronary artery bypass grafting.
MedLine Citation:
PMID:  6132568     Owner:  NLM     Status:  MEDLINE    
Vecuronium is a new nondepolarizing muscle relaxant which has been shown to cause no significant cardiovascular effects. Utilizing invasive monitoring in patients undergoing coronary artery bypass grafting, the authors compared the cardiovascular effects of vecuronium (0.28 mg/kg) in seven anesthetized patients with those of pancuronium (0.1 mg/kg) in five anesthetized patients. This dose of pancuronium represents three times its ED90 (dose producing a 90% depression of evoked twitch tension), while the vecuronium dose represents twelve times its ED90. This relatively large dose of vecuronium was chosen deliberately in an attempt to manifest any possible cardiovascular effects. Following administration of vecuronium, cardiac output increased 9% and systemic vascular resistance decreased 12%, while pancuronium produced a significantly greater 17% increase in cardiac output without change in systemic vascular resistance. Heart rate and systemic mean arterial pressure did not change following vecuronium, while increasing 22% and 24%, respectively, following pancuronium. The authors conclude that large doses of vecuronium have minimal cardiovascular effects and thus offer an advantage over pancuronium in patients anesthetized for coronary artery surgery.
R B Morris; M K Cahalan; R D Miller; P L Wilkinson; A L Quasha; S L Robinson
Related Documents :
2881568 - Haemodynamic effects of vecuronium, pancuronium and atracurium in patients with coronar...
2849968 - Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action.
10605918 - Laryngeal chemodenervation: effects of injection site, dose, and volume.
7378868 - Suxamethonium-induced jaw stiffness and myalgia associated with atypical cholinesterase...
10932788 - Aflatoxin b1 residues in eggs of laying hens fed a diet containing different levels of ...
24337978 - Randomised, double-blind, placebo-controlled, dose-escalating phase i study of qgc001, ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anesthesiology     Volume:  58     ISSN:  0003-3022     ISO Abbreviation:  Anesthesiology     Publication Date:  1983 May 
Date Detail:
Created Date:  1983-05-27     Completed Date:  1983-05-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1300217     Medline TA:  Anesthesiology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  438-40     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Coronary Artery Bypass*
Coronary Disease / drug therapy,  surgery
Hemodynamics / drug effects*
Intraoperative Complications
Nitrous Oxide
Pancuronium / adverse effects*,  analogs & derivatives*
Vecuronium Bromide
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Pancuronium; 10024-97-2/Nitrous Oxide; 151-67-7/Halothane; 50700-72-6/Vecuronium Bromide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characterization of the train-of-four response in fast and slow muscles: effect of d-tubocurarine, p...
Next Document:  Greater inhibition of dermographia with a combination of H1 and H2 antagonists.